Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVA22007 extension study after treatment discontinuation in severe dry eye disease
2012-002066-12Phase 3Completed
- Sponsor
- Novagali Pharma
- Start
- Oct 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclosporine in dry eye syndrome (DED), sponsored by Novagali Pharma. Primary endpoint: Time to relapse following NOVA22007 treatment discontinuation. Started Oct 2012; status: completed.
02
Drugs
cyclosporine
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on 2012-002066-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002066-12.